SCHEMBL20524441

SCHEMBL20524441

CCN(CC(=O)c1ccccn1)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
NAPRT Q6XQN6 1/20 0.49
P4HTM Q9NXG6 1/20 0.49
ALDH1A1 P00352 3/20 0.47
CTNNB1 P35222 3/20 0.47
WNT3A P56704 2/20 0.47
CES2 O00748 1/20 0.46
CES1 P23141 1/20 0.46
KMT2A Q03164 2/20 0.45
OPRD1 P41143 1/20 0.44
KCNH2 Q12809 1/20 0.44
GRM4 Q14833 1/20 0.43
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
PKM P14618 2/20 0.42
MITF O75030 1/20 0.42
CDK5 Q00535 1/20 0.42
CDK5R1 Q15078 1/20 0.42
HPGD P15428 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20524453 0.81 LMNA (0.52) LMNAL3MBTL1NAPRTP4HTMALDH1A1
SCHEMBL17005191 0.81 L3MBTL1 (0.45) LMNAL3MBTL1NAPRTP4HTMALDH1A1
SCHEMBL24443482 0.80 NPC1 (0.42) LMNAL3MBTL1NAPRTP4HTMALDH1A1
SCHEMBL29689910 0.80 NPC1 (0.42) LMNAL3MBTL1NAPRTP4HTMALDH1A1
SCHEMBL5161505 0.79 ALDH1A1 (0.49) LMNAL3MBTL1NAPRTP4HTMALDH1A1
SCHEMBL30975214 0.78 ALDH1A1 (0.58) LMNAL3MBTL1NAPRTP4HTMALDH1A1
SCHEMBL8405203 0.78 ALDH1A1 (0.58) LMNAL3MBTL1NAPRTP4HTMALDH1A1
SCHEMBL20524414 0.76 ALDH1A1 (0.54) LMNAL3MBTL1ALDH1A1CES1KMT2A
SCHEMBL156496 0.76 ALDH1A1 (0.61) LMNAL3MBTL1NAPRTP4HTMALDH1A1
SCHEMBL29433442 0.76 ALDH1A1 (0.61) LMNAL3MBTL1NAPRTP4HTMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11339140-B2 Compositions and methods comprising substituted 2-aminoimidazoles CURZA GLOBAL, LLC (US) 2022-05-24 US disclosed
EP-3601232-A1 COMPOSITIONS AND METHODS COMPRISING SUBSTITUTED 2-AMINOIMIDAZOLES Curza Global LLC (US) 2020-02-05 EP disclosed
WO-2018184019-A1 COMPOSITIONS AND METHODS COMPRISING SUBSTITUTED 2-AMINOIMIDAZOLES CURZA GLOBAL, LLC (US) 2018-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11339140-B2 Compositions and methods comprising substituted 2-aminoimidazoles AADAC, PAICS, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 LMNA 2193/4885L3MBTL1 3726/4885NAPRT 2653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.